Opsens Inc (OPSSF) 1.1000 $OPSSF
Opsens Announces Fiscal 2016 Third Quarter Results - Sales of $2,125,000, up 156% Year-Over-Year
CNW Group - Tue Jul 05, 6:00AM CDT
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF) today released the results of its third quarter ended May 31, 2016.
OPS.VN: 1.540 (+0.050)
Opsens announces results for its second quarter 2016
CNW Group - Tue Apr 19, 6:00AM CDT
Opsens Inc. ("Opsens" or the "Company" (TSXV: OPS) (OTCQX: OPSSF) today released the results for its second quarter ended February 29, 2016.
OPS.VN: 1.540 (+0.050)
Opsens receives FDA 510(k) clearance for the OptoWire II
CNW Group - Wed Mar 16, 7:00AM CDT
Opsens Inc. ("Opsens" or the "Company" (TSXV: OPS) (OTCQX: OPSSF) today announces the 510(k) clearance from the U.S. Food and Drug Administration ("FDA" for the OptoWire II, an optical guidewire developed to measure Fractional Flow Reserve ("FFR" . FFR measurement is used for the diagnostic of the severity of coronary stenosis for guiding the treatment of patients with coronary artery disease.
OPS.VN: 1.540 (+0.050)
OPSENS named to the 2016 TSX Venture TOP 50®
CNW Group - Tue Mar 08, 12:28PM CST
Opsens Inc. ("Opsens" or the "Company" (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce that it has been recognized in the top performing Technology companies in the 2016 TSX Venture 50®. The TSX Venture 50® ranks the top 10 companies in five major industry sectors, identifying the ones that have shown strong results on three equally weighted criteria of market performance: market capitalization growth, share price appreciation and trading volume.
OPS.VN: 1.540 (+0.050)
Opsens reports Q1 2016 results
CNW Group - Tue Jan 19, 7:00AM CST
Opsens Inc. ("Opsens" or the "Company" (TSXV: OPS) (OTCQX: OPSSF) today released the results of its first quarter ended November 30, 2015.
OPS.VN: 1.540 (+0.050)
Global Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020) - Estimated at $14 Billion By 2018
M2 - Tue Dec 22, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wklcm6/global_biomedical) has announced the addition of the "Global Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" report to their offering. The Biomedical Sensors market is estimated at $14.58 billion by 2018 at a CAGR of 6.05% over the period 2014-2020. The near future will bring biomedical sensors that are adaptable to the genetic formulation of each individual. These sensors can be set to trigger alerts when unpredictable readings are enlisted, screen the existence of toxic agents in the blood, or empower drug directly into the circulatory system. These Sensors are set to find its demand in the healthcare industry. The Biomedical Sensors are driven by the increased demand in the hazardous environments, utilization in situations resulting natural disasters, increased demand in healthcare sector for diabetic and heart patients, and embedded monitoring of the patients. The advancement in technology has made possible to build a Biomedical Sensor using Nano and Micro technology making it tiny, robust, smart and cost-effective. The early detection of irregularities in the health status of the patients will contribute to the better quality of life. Even though Biomedical Sensors are playing a major role in life saving situation, it is facing certain challenges such as patient's safety and comfort due to strong electromagnetic fields, transferring energy from external to internal parts with high efficiency and high data rates, limited computation and data storage, and ultra-low power consumption. North America remains the largest market for Biomedical Sensors market, followed by Asia Pacific and Europe. France leads the European market and China and Japan leads the Asia Pacific market, and Indian Biomedical Sensor is showing the highest growth. Key Topics Covered: 1. Introduction 2. Key Findings 3. Market Overview & Dynamics 4. Introduction 5. Porter's Five Forces Analysis 6. Market Segmentation 7. Market Segmentation, By Region 8. Company Profiles 9. Investment Analysis 10. Future of Biomedical Sensors Market Companies Mentioned: - Zephyr Technology Corp. - Entra Health Systems - Fiso Technologies Inc. - Lumasense Technologies - Neoptix - Opsens,Inc. - Rjc Enterprises Llc - Infraredx, Inc. - Iss, Inc. - Srico - Adinstruments - Maquet - Nonin Medical Inc. - Hansen Medical - Measurand Inc. For more information visit http://www.researchandmarkets.com/research/wk...biomedical
HNSN: 3.97 (unch)
Opsens Receives Orders Worth $1.2 Million for its FFR Products from Japan
CNW Group - Mon Nov 30, 7:00AM CST
Opsens Inc. ("Opsens" or the "Company" (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce receipt of orders worth over $1.2 million for its products to measure Fractional Flow Reserve ("FFR" from the Japanese market. Opsens' FFR products are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease.
OPS.VN: 1.540 (+0.050)
Opsens granted approval to sell OptoWire II in Japan
CNW Group - Thu Nov 26, 12:12PM CST
Opsens Inc. ("Opsens" or the "Company" (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce that its Japanese partner has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare ("MHLW" to sell the OptoWire II.
OPS.VN: 1.540 (+0.050)
Opsens reports 2015 results
CNW Group - Tue Nov 24, 7:00AM CST
Opsens Inc. ("Opsens" (TSXV: OPS) (OTCQX: OPSSF) today released results for the year ended August 31, 2015.
OPS.VN: 1.540 (+0.050)
OPSENS granted approval to sell OptoWire II in Europe
CNW Group - Thu Nov 12, 9:22AM CST
Opsens Inc. ("Opsens" or the "Company" (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce it has been granted CE marking for the OptoWire II, the improved version of its pressure guidewire (OptoWire I) developed to measure Fractional Flow Reserve ("FFR" in patients with coronary artery disease. CE marking allows Opsens to sell OptoWire II in Europe, the world's second largest market.
OPS.VN: 1.540 (+0.050)
Opsens announces first use of its FFR products in the United States
CNW Group - Wed Nov 11, 7:00AM CST
Opsens Inc. ("Opsens" or the "Company" (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that the OptoWire and OptoMonitor, its products to measure Fractional Flow Reserve ("FFR" , were used for the first time in the United States by Dr. Morton J. Kern and Dr. Arnold Seto at the University of California, Irvine and VA Long Beach, California. Opsens' FFR products are designed for the diagnostic of the functional severity of coronary stenoses and to guide their treatment.
OPS.VN: 1.540 (+0.050)
Opsens performs 1,000th procedure with the OptoWire
CNW Group - Wed Oct 28, 7:00AM CDT
Opsens Inc. ("Opsens" or the "Company" (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that the OptoWire, its guidewire to measure Fractional Flow Reserve ("FFR" , which is designed to optimize and guide treatment in patients with coronary heart disease, has been used as a diagnostic tool by cardiologists in 1,000 patients, marking a milestone for the Company.
OPS.VN: 1.540 (+0.050)
Opsens Presentation Now Available for On-Demand Viewing
CNW Group - Tue Oct 06, 7:00AM CDT
Opsens Inc. ("Opsens" or the "Company" (TSXV:OPS) (OTCQX:OPSSF), a company focusing on the measure of Fractional Flow Reserve ("FFR" in interventional cardiology, today announced that the October 1 presentation from Louis Laflamme, President and Chief Executive Officer, is now available for on-demand viewing at VirtualInvestorConferences.com. During this presentation, Mr. Laflamme provides a corporate overview, including recent development on the Company.
OPS.VN: 1.540 (+0.050)
Opsens to Present Live Via Webcast at VirtualInvestorConferences.com on October 1, 2015 at 9:15am ET
PR Newswire - Tue Sep 29, 10:36AM CDT
Opsens Inc. ("Opsens" or the "Company" (TSXV: OPS) (OTCQX: OPSSF), a company focusing on the measure of Fractional Flow Reserve ("FFR" in interventional cardiology, announced today that Louis Laflamme, President and Chief Executive Officer, will present at VirtualInvestorConferences.com hosted by the OTC Markets Group, on Thursday, October 1, 2015, at 9:15 a.m. ET.
OPS.VN: 1.540 (+0.050)
OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies - October 1
PR Newswire - Mon Sep 28, 8:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets for 10,000 U.S. and global securities, today announced its second in a series of online investor conferences for companies traded on the OTCQX® Best Market through its partnership with VirtualInvestorConferences.com, a cooperative venture of PR Newswire and Better Investing(TM).
CDXC: 3.81 (-0.18)
Opsens hires Tony Gibbons as Vice President, Sales and Marketing
CNW Group - Wed Sep 16, 8:36AM CDT
Opsens Inc. ("Opsens" or the "Company" (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce the hiring of Tony Gibbons as Vice President, Sales and Marketing. He will be responsible for the global commercialization plan for Opsens' products intended to measure Fractional Flow Reserve ("FFR" . Opsens' FFR Products, the OptoWire and OptoMonitor, are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease.
BSX: 23.66 (-0.01), OPS.VN: 1.540 (+0.050)
Opsens announces the resignation of a director
CNW Group - Wed Sep 16, 8:26AM CDT
Opsens Inc. ("Opsens" or the "Company" (TSXV:OPS) (OTCQX:OPSSF) announces the resignation of Lucien Goffart. As part of the progression of his career, Mr. Goffart is now involved in projects that are incompatible with his Director's responsibilities at Opsens.
OPS.VN: 1.540 (+0.050)
Opsens Announces a Reorganization of its Corporate Structure
CNW Group - Thu Sep 03, 7:00AM CDT
Opsens Inc. ("Opsens" or the "Company" (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce the reorganization of its corporate structure.
OPS.VN: 1.540 (+0.050)
Opsens Announces Fiscal 2016 Third Quarter Results - Sales of $2,125,000, up 156% Year-Over-Year
CNW Group - Tue Jul 05, 6:00AM CDT
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF) today released the results of its third quarter ended May 31, 2016. OPS.VN: 1.540 (+0.050)
Opsens announces results for its second quarter 2016
CNW Group - Tue Apr 19, 6:00AM CDT
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF) today released the results for its second quarter ended February 29, 2016. OPS.VN: 1.540 (+0.050)
Opsens receives FDA 510(k) clearance for the OptoWire II
CNW Group - Wed Mar 16, 7:00AM CDT
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF) today announces the 510(k) clearance from the U.S. Food and Drug Administration ("FDA" for the OptoWire II, an optical guidewire developed to measure Fractional Flow Reserve ("FFR" . FFR measurement is used for the diagnostic of the severity of coronary stenosis for guiding the treatment of patients with coronary artery disease. OPS.VN: 1.540 (+0.050)
OPSENS named to the 2016 TSX Venture TOP 50®
CNW Group - Tue Mar 08, 12:28PM CST
Opsens Inc. ("Opsens" or the "Company"
(TSXV:OPS) (OTCQX:OPSSF) is pleased to announce that it has been recognized in the top performing Technology companies in the 2016 TSX Venture 50®. The TSX Venture 50® ranks the top 10 companies in five major industry sectors, identifying the ones that have shown strong results on three equally weighted criteria of market performance: market capitalization growth, share price appreciation and trading volume. OPS.VN: 1.540 (+0.050)
Opsens reports Q1 2016 results
CNW Group - Tue Jan 19, 7:00AM CST
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF) today released the results of its first quarter ended November 30, 2015. OPS.VN: 1.540 (+0.050)
Global Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020) - Estimated at $14 Billion By 2018
M2 - Tue Dec 22, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wklcm6/global_biomedical) has announced the addition of the "Global Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" report to their offering. The Biomedical Sensors market is estimated at $14.58 billion by 2018 at a CAGR of 6.05% over the period 2014-2020. The near future will bring biomedical sensors that are adaptable to the genetic formulation of each individual. These sensors can be set to trigger alerts when unpredictable readings are enlisted, screen the existence of toxic agents in the blood, or empower drug directly into the circulatory system. These Sensors are set to find its demand in the healthcare industry. The Biomedical Sensors are driven by the increased demand in the hazardous environments, utilization in situations resulting natural disasters, increased demand in healthcare sector for diabetic and heart patients, and embedded monitoring of the patients. The advancement in technology has made possible to build a Biomedical Sensor using Nano and Micro technology making it tiny, robust, smart and cost-effective. The early detection of irregularities in the health status of the patients will contribute to the better quality of life. Even though Biomedical Sensors are playing a major role in life saving situation, it is facing certain challenges such as patient's safety and comfort due to strong electromagnetic fields, transferring energy from external to internal parts with high efficiency and high data rates, limited computation and data storage, and ultra-low power consumption. North America remains the largest market for Biomedical Sensors market, followed by Asia Pacific and Europe. France leads the European market and China and Japan leads the Asia Pacific market, and Indian Biomedical Sensor is showing the highest growth. Key Topics Covered: 1. Introduction 2. Key Findings 3. Market Overview & Dynamics 4. Introduction 5. Porter's Five Forces Analysis 6. Market Segmentation 7. Market Segmentation, By Region 8. Company Profiles 9. Investment Analysis 10. Future of Biomedical Sensors Market Companies Mentioned: - Zephyr Technology Corp. - Entra Health Systems - Fiso Technologies Inc. - Lumasense Technologies - Neoptix - Opsens,Inc. - Rjc Enterprises Llc - Infraredx, Inc. - Iss, Inc. - Srico - Adinstruments - Maquet - Nonin Medical Inc. - Hansen Medical - Measurand Inc. For more information visit http://www.researchandmarkets.com/research/wk...biomedical
HNSN: 3.97 (unch)
Opsens Receives Orders Worth $1.2 Million for its FFR Products from Japan
CNW Group - Mon Nov 30, 7:00AM CST
Opsens Inc. ("Opsens" or the "Company"
(TSXV:OPS) (OTCQX:OPSSF) is pleased to announce receipt of orders worth over $1.2 million for its products to measure Fractional Flow Reserve ("FFR" from the Japanese market. Opsens' FFR products are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease. OPS.VN: 1.540 (+0.050)
Opsens granted approval to sell OptoWire II in Japan
CNW Group - Thu Nov 26, 12:12PM CST
Opsens Inc. ("Opsens" or the "Company"
(TSXV:OPS) (OTCQX:OPSSF) is pleased to announce that its Japanese partner has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare ("MHLW" to sell the OptoWire II. OPS.VN: 1.540 (+0.050)
Opsens reports 2015 results
CNW Group - Tue Nov 24, 7:00AM CST
Opsens Inc. ("Opsens"
(TSXV: OPS) (OTCQX: OPSSF) today released results for the year ended August 31, 2015. OPS.VN: 1.540 (+0.050)
OPSENS granted approval to sell OptoWire II in Europe
CNW Group - Thu Nov 12, 9:22AM CST
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF) is pleased to announce it has been granted CE marking for the OptoWire II, the improved version of its pressure guidewire (OptoWire I) developed to measure Fractional Flow Reserve ("FFR" in patients with coronary artery disease. CE marking allows Opsens to sell OptoWire II in Europe, the world's second largest market. OPS.VN: 1.540 (+0.050)
Opsens announces first use of its FFR products in the United States
CNW Group - Wed Nov 11, 7:00AM CST
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that the OptoWire and OptoMonitor, its products to measure Fractional Flow Reserve ("FFR" , were used for the first time in the United States by Dr. Morton J. Kern and Dr. Arnold Seto at the University of California, Irvine and VA Long Beach, California. Opsens' FFR products are designed for the diagnostic of the functional severity of coronary stenoses and to guide their treatment. OPS.VN: 1.540 (+0.050)
Opsens performs 1,000th procedure with the OptoWire
CNW Group - Wed Oct 28, 7:00AM CDT
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that the OptoWire, its guidewire to measure Fractional Flow Reserve ("FFR" , which is designed to optimize and guide treatment in patients with coronary heart disease, has been used as a diagnostic tool by cardiologists in 1,000 patients, marking a milestone for the Company. OPS.VN: 1.540 (+0.050)
Opsens Presentation Now Available for On-Demand Viewing
CNW Group - Tue Oct 06, 7:00AM CDT
Opsens Inc. ("Opsens" or the "Company"
(TSXV:OPS) (OTCQX:OPSSF), a company focusing on the measure of Fractional Flow Reserve ("FFR" in interventional cardiology, today announced that the October 1 presentation from Louis Laflamme, President and Chief Executive Officer, is now available for on-demand viewing at VirtualInvestorConferences.com. During this presentation, Mr. Laflamme provides a corporate overview, including recent development on the Company. OPS.VN: 1.540 (+0.050)
Opsens to Present Live Via Webcast at VirtualInvestorConferences.com on October 1, 2015 at 9:15am ET
PR Newswire - Tue Sep 29, 10:36AM CDT
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF), a company focusing on the measure of Fractional Flow Reserve ("FFR" in interventional cardiology, announced today that Louis Laflamme, President and Chief Executive Officer, will present at VirtualInvestorConferences.com hosted by the OTC Markets Group, on Thursday, October 1, 2015, at 9:15 a.m. ET. OPS.VN: 1.540 (+0.050)
OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies - October 1
PR Newswire - Mon Sep 28, 8:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets for 10,000 U.S. and global securities, today announced its second in a series of online investor conferences for companies traded on the OTCQX® Best Market through its partnership with VirtualInvestorConferences.com, a cooperative venture of PR Newswire and Better Investing(TM).
CDXC: 3.81 (-0.18)
Opsens hires Tony Gibbons as Vice President, Sales and Marketing
CNW Group - Wed Sep 16, 8:36AM CDT
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF) is pleased to announce the hiring of Tony Gibbons as Vice President, Sales and Marketing. He will be responsible for the global commercialization plan for Opsens' products intended to measure Fractional Flow Reserve ("FFR" . Opsens' FFR Products, the OptoWire and OptoMonitor, are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease. BSX: 23.66 (-0.01), OPS.VN: 1.540 (+0.050)
Opsens announces the resignation of a director
CNW Group - Wed Sep 16, 8:26AM CDT
Opsens Inc. ("Opsens" or the "Company"
(TSXV:OPS) (OTCQX:OPSSF) announces the resignation of Lucien Goffart. As part of the progression of his career, Mr. Goffart is now involved in projects that are incompatible with his Director's responsibilities at Opsens. OPS.VN: 1.540 (+0.050)
Opsens Announces a Reorganization of its Corporate Structure
CNW Group - Thu Sep 03, 7:00AM CDT
Opsens Inc. ("Opsens" or the "Company"
(TSXV: OPS) (OTCQX: OPSSF) is pleased to announce the reorganization of its corporate structure. OPS.VN: 1.540 (+0.050)
